Collected Dataset / VISID_Vaccine_experienced_subgroupA_Visit2

The population is composed of patients who are 12 years old and older, vaccine experienced and have a predominant B cell defect. These patiens have a primary antibody deficiency including but not limited to common variable immunodeficiency and x-linked agammaglobulinemia who are being treated or recently treated ( less than 6 months) with B-cell depleting therapy (e.g. rituximab, ocrelizumab) or with B-cell activating factor inhibitor (e.g. belimumab), including patients with immune-mediated diseases such as multiple sclerosis, rheumatoid arthritis, and granulomatous polyangiitis as well as patients with hematological malignancies such as non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.

Information was collected about medical history, physical examination, concomitant medications and adverse events. A blood sample was collected.